![]() | |
Names | |
---|---|
IUPAC name (4S,5R)-5-[3,5-bis(trifluoromethyl)phenyl]-4-methyl-3-(2-naphthalen-1-ylacetyl)-1,3-oxazolidin-2-one | |
Identifiers | |
ChEBI | |
ChEMBL | |
ChemSpider | |
PubChem CID | |
| |
| |
Properties | |
C24H17F6NO3 | |
Molar mass | 481.394 g·mol−1 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). |
![]() | |
Names | |
---|---|
IUPAC name 3-(2-cyclohexylbenzimidazol-1-yl)-N-[(1R,2R,4R)-1,7,7-trimethyl-2-bicyclo[2.2.1]heptanyl]propanamide | |
Identifiers | |
ChEBI | |
ChEMBL | |
ChemSpider | |
PubChem CID | |
| |
| |
Properties | |
C26H37N3O | |
Molar mass | 407.602 g·mol−1 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). |
Tarocin A and tarocin B are two structurally unrelated compounds that inhibit the TarO enzyme involved in teichoic acid biosynthesis in bacteria. [1]
Using either of them with β-lactam antibiotics seems to be effective in mice against some β-lactam-resistant bacteria. [1]
Because the tarocins lack activity when used alone it may simplify the clinical trials for approval for medical use. [1]